An interventional study of Screening Cancer Readiness through Education and Empowerment for Newcomer Women and Control group in Cancer Screening, Early Detection of Cancer and Migrants, sponsored by Erzincan Binali Yildirim Universitesi. Not yet recruiting. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Erzincan Binali Yildirim Universitesi · Not applicable, Interventional, and Supportive care
Purpose: This study was conducted to determine the effect of an online educational intervention on migrant women's knowledge and attitudes toward cancer screening.
DesigN:This study was designed as a two-arm, parallel-group, randomized controlled trial with pre-test and post-test assessments.
Method: The study population will consist of women registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) affiliated with the Erzincan Provincial Health Directorate. The sample size was calculated based on a two-group (intervention and control) and two-measurement (pre-test and post-test) study design. Using repeated-measures ANOVA with a medium effect size (d = 0.25), a significance level of 5% (α = 0.05), and a statistical power of 80% (1 - β = 0.80), the required sample size was determined to be 34 participants per group (34 in the intervention group and 34 in the control group), resulting in a minimum total sample of 68 participants. To account for potential attrition, it was planned to recruit 80 participants (approximately 20% more than the minimum required sample size).
1,573 studies on the registry are indexed under Behavior; 313 are open to participants now.
This study's planned enrollment of 80 is below the median of 120 across 1,197 interventional studies indexed under Behavior.
Browse Behavior studies →Erzincan Binali Yildirim Universitesi is the lead sponsor of 23 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Women aged 30-70 years. Able to read and write. Able to speak and understand Turkish. Have access to the internet at home or in the workplace. Own a smartphone or have access to a smartphone belonging to a family member that can be used by the participant.
Have no hearing, visual, cognitive, or orthopedic impairments that would prevent participation in the study.
-
Exclusion Criteria:Presence of cognitive, visual, or orthopedic impairment that may interfere with participation in the study.
Diagnosis of a psychiatric disorder.
-
Other: Screening Cancer Readiness through Education and Empowerment for Newcomer Women
Other: Control group
Women assigned to the intervention group will be contacted by telephone using the contact information registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM). For participants without a registered telephone number, home visits will be conducted using the addresses recorded in the KETEM database. Following completion of the baseline (pre-test) assessment, participants in the intervention group will receive an online cancer screening education program developed in accordance with the Turkish National Cancer Control Program of the General Directorate of Public Health, Ministry of Health of the Republic of Türkiye. The educational intervention will be delivered in three online sessions via WhatsApp video calls. During each session, participants will have the opportunity to ask questions, which will be answered by the researcher. Prior to each session, reminder text messages will be sent to participants' mobile phones to notify them of the date and time of the schede
Women assigned to the control group who are registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) will be contacted and invited to participate in the study. During the initial meeting, written informed consent will be obtained, after which the Personal Information Form and study questionnaires will be administered to collect baseline (pre-test) data. An appointment for the follow-up assessment will be scheduled approximately four weeks later. Five weeks after the baseline assessment, participants will be contacted by telephone to complete the post-test assessment. No educational intervention will be provided to the control group during the study period. After completion of the post-test assessment, participants in the control group will be offered the same cancer screening education program in accordance with the ethical principle of equity.
Cancer Screening Knowledge Scale
The Cancer Screening Knowledge Scale is a 25-item questionnaire designed to assess participants' knowledge regarding cancer screening. Total scores range from 0 to 25, with higher scores indicating greater knowledge.
Time frame: From baseline to 5 weeks after baseline
Cancer Screening Attitude Scale-Short Form
The Cancer Screening Attitude Scale-Short Form is a 15-item questionnaire used to assess participants' attitudes toward cancer screening. Total scores range from 15 to 75, with higher scores indicating more positive attitudes toward cancer screening.
Time frame: From baseline to 5 weeks after baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.
Of 741 non-industry interventional studies with no phase under Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 4 months is below that.
Counting every sponsor, half of 757 studies reached it within 13 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erzincan Binali Yildirim Universitesi